ReportsCancer

Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma

See allHide authors and affiliations

Science Translational Medicine  28 Jun 2017:
Vol. 9, Issue 396, eaak9969
DOI: 10.1126/scitranslmed.aak9969

Article Information

vol. 9 no. 396

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication September 27, 2016
  • Resubmitted February 3, 2017
  • Accepted for publication June 5, 2017

Author Information

  1. Elisa Oricchio1,*,
  2. Natalya Katanayeva1,
  3. Maria Christine Donaldson1,
  4. Stephanie Sungalee1,
  5. Joyce P. Pasion2,
  6. Wendy Béguelin3,
  7. Elena Battistello1,4,
  8. Viraj R. Sanghvi2,
  9. Man Jiang2,
  10. Yanwen Jiang5,
  11. Matt Teater5,
  12. Anita Parmigiani6,
  13. Andrei V. Budanov6,7,
  14. Fong Chun Chan8,9,
  15. Sohrab P. Shah10,11,
  16. Robert Kridel8,12,
  17. Ari M. Melnick3,
  18. Giovanni Ciriello4 and
  19. Hans-Guido Wendel2
  1. 1Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
  2. 2Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  3. 3Division of Hematology/Oncology, Weill Cornell Medical College, Cornell University, 1300 York Avenue, New York, NY 10065, USA.
  4. 4Department of Computational Biology, University of Lausanne, 1005 Lausanne, Switzerland.
  5. 5Institute for Computational Biomedicine, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA.
  6. 6Department of Human and Molecular Genetics, Goodwin Research Laboratories, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  7. 7School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin 2, Ireland.
  8. 8Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada.
  9. 9Bioinformatics Graduate Program, University of British Columbia, Vancouver, British Columbia, Canada.
  10. 10Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  11. 11Department of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
  12. 12Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  1. *Corresponding author. Email: elisa.oricchio{at}epfl.ch

Altmetric

Article usage

Article usage: June 2017 to November 2018

AbstractFullPdf
Jun 2017187769202
Jul 20172607143278
Aug 20173315063
Sep 20172181651
Oct 20171842821
Nov 20172081937
Dec 20172131315
Jan 20182222112
Feb 2018126927
Mar 20181172128
Apr 2018941716
May 2018118619
Jun 2018152928
Jul 2018854552
Aug 2018013446
Sep 2018020342
Oct 2018016484
Nov 2018013424

Navigate This Article